The Pharmaceutical Market: Slovenia

Date: January 31, 2013
Pages: 93
Price:
US$ 1,295.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P8A1A10B192EN
Leaflet:

Download PDF Leaflet

The Pharmaceutical Market: Slovenia
OVERVIEW OF THE PHARMACEUTICAL MARKET IN SLOVENIA

Slovenia's healthcare system is relatively developed and effective, particularly compared with other markets in Central and Eastern Europe. The country's health system faces short-term challenges as a result of austerity budgets which will limit public spending on healthcare andaredesigned to reduce the number of services covered under compulsory health insurance. Long-term threats concern the availability of public funds in a tightening economic and fiscal environment and projected rises in age-related health expenditure.

Headline Expenditure Projections

Pharmaceuticals: EUR762mn (US$1.06mn) in 2011 to EUR769mn (US$977mn) in 2012; +1.0% in local currency terms and -7.8% in US dollar terms.

Healthcare: EUR3.40bn (US$4.73bn) in 2011 to EUR3.42bn (US$4.34bn) in 2012; 0.5% in local currency terms and -8.2% in US dollar terms.

Medical devices: EUR235mn (US$327mn) in 2011 to EUR239mn (US$304mn) in 2012; +1.5% in local currency terms and -7.3% in US dollar terms.

Risk/Reward Rating: In our Q1 13 assessment, we have revised downward our Pharmaceuticals and HealthcareRisk/Reward Ratings (RRRs)forCentral and Eastern Europe (CEE), mainly due to the attractiveness of Poland, Greece and the Czech Republic getting worse.Downward revisions to our industry rewards indicators for CEE are a result of moderated outlooks for 2013 in many pharmaceutical markets, as well unfavourable revisions to our currency assumptions, affecting our assessment of market growth when measured in US dollars. Slovenia's Risk/Reward Rating (RRR) score remains weak - a combination of economic factors and the acknowledgement that the government may retain its focus on cost savings have resulted in a slightly less optimistic outlook for 2013 and 2014.

Competitive Landscape

The Competitive Landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of Espicom's industry forecasts, our macroeconomic views and our understanding of the wider Competitive Landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the Company Profiles, enabling a full evaluation of recent company performance and future growth prospects.
EXECUTIVE SUMMARY

SWOT ANALYSIS

      Slovenia Pharmaceuticals And Healthcare Industry SWOT
      Slovenia Political SWOT
      Slovenia Economic SWOT
      Slovenia Business Environment SWOT

PHARMACEUTICAL RISK/REWARD RATINGS

      Table: Emerging Europe Pharmaceutical Risk/Reward Ratings, Q113
      Rewards
      Risks

SLOVENIA – MARKET SUMMARY

REGULATORY REGIME

      Intellectual Property Regime
      Pricing Regime
      Reimbursement Regime

INDUSTRY DEVELOPMENTS

      Epidemiology
      Healthcare Sector
      Hospital Infrastructure
      Table: Hospitals & Beds, 2009
      Ambulatory Infrastructure
  Services
      Hospital Inpatient Services
      Table: Activity by Hospital Type, 1995-2009
      Outpatient Services
      Table: Outpatient Visits to Primary Care Facilities by Cause, 2005-2009
  Workforce
      Projections
      Table: Regional Comparison of Projected Physicians, 2016
      Table: Projected Physicians, 2011-2016
      Physicians
      Table: Physicians, 2000-2008
      Nurses
      Table: Nurses, 2000-2008
      Public Healthcare Expenditure
      Healthcare Insurance
      Healthcare Insurance Reforms
      Pharmaceutical Distribution
      Table: Slovenian Chamber of Commerce Members, 2010
      Table: IRIS Suppliers, 2011
      Clinical Trials
      Biotechnology
      Medical Devices
      Slovenia Pharmaceuticals & Healthcare Report Q1 2013

INDUSTRY FORECAST SCENARIO

      Overall Market Forecast
      Table: Pharmaceutical Sales Indicators 2009-2016
      Healthcare Market Forecast
      Table: Healthcare Expenditure Indicators 2008-2016
      Table: Healthcare Governmental Indicators 2008-2016
      Table: Healthcare Private Indicators 2008-2016
      Key Growth Factors – Macroeconomic
      Table: SLOVENIA - ECONOMIC ACTIVITY
      Prescription Drug Market Forecast
      Table: Prescription Drug Sales Indicators 2008-2016
      Patented Drug Market Forecast
      Table: Patented Drug Market Indicators 2008-2016
      Generic Drug Market Forecast
      Table: Generic Drug Sales Indicators 2008-2016
      OTC Medicine Market Forecast
      Table: OTC Medicine Sales Indicators 2008-2016
      Pharmaceutical Trade Forecast
      Table: Exports and Imports Indicators 2008-2016
      Medical Device Market Forecast
      Table: Medical Devices Sales Indicators 2008-2016
      Key Risks to BMI’s Forecast Scenario

COMPETITIVE LANDSCAPE

      Pharmaceutical Industry
      Table: Manufacturing Indicators, 2005-2009
      Recent Pharmaceutical Industry Developments

COMPANY MONITOR

  Local Company Profiles
      Krka
      Lek (Novartis/Sandoz)
  Multinational Company Profiles
      GlaxoSmithKline
      Sanofi
      Pfizer
      Novartis
      Merck & Co

DEMOGRAPHIC OUTLOOK

      Slovenia – Population By Age Group, 1990-2020
      Slovenia – Population By Age Group, 1990-2020
      Slovenia – Key Population Ratios, 1990-2020
      Slovenia – Rural and Urban Population, 1990-2020

GLOSSARY

BMI METHODOLOGY

      How We Generate Our Pharmaceutical Industry Forecasts

PHARMACEUTICALS BUSINESS ENVIRONMENT RATINGS

RISK/REWARD RATINGS METHODOLOGY

RATINGS OVERVIEW

TABLE: PHARMACEUTICAL BUSINESS ENVIRONMENT INDICATORS

WEIGHTING

TABLE: WEIGHTING OF COMPONENTS

SOURCES
Skip to top


The Pharmaceutical Market: Finland US$ 1,295.00 Mar, 2013
The Pharmaceutical Market: France US$ 1,295.00 Jan, 2013 · 107 pages
The Pharmaceutical Market: Germany US$ 1,295.00 Jan, 2013 · 112 pages

Ask Your Question

The Pharmaceutical Market: Slovenia
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: